AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference

Rhea-AI Summary

AzurRx BioPharma (NASDAQ: AZRX) will participate in the Biotech Showcase Digital 2021 conference from January 11-15, 2021. James Sapirstein, President & CEO, alongside the senior management team, will engage in virtual one-on-one meetings with investors to discuss the company's business and clinical development programs, highlighting anticipated milestones for 2021. AzurRx specializes in developing targeted therapies for gastrointestinal diseases, including its lead candidate MS1819 for treating exocrine pancreatic insufficiency.

DELRAY BEACH, Fla., Jan. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in this year’s Biotech Showcase Digital 2021 conference.

James Sapirstein, President & CEO of AzurRx BioPharma, and the Company’s senior management team will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. The AzurRx team will be available to provide an overview of the Company’s business and clinical development programs and discuss anticipated 2021 milestones.

Details of the event are as follows:

Event:		Biotech Showcase Digital
Date:		January 11-15, 2021
Registration:		https://informaconnect.com/biotech-showcase/registration-options/

About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. Additional information on the Company can be found at www.azurrx.com.

Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results, including those related to the clinical development of its clinical assets, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: (617) 430-7578 
hans@lifesciadvisors.com

FAQ

What is AzurRx BioPharma's participation in the Biotech Showcase Digital 2021?

AzurRx BioPharma will participate in the Biotech Showcase Digital 2021 conference from January 11-15, 2021, engaging in virtual meetings with investors.

Who will represent AzurRx at the Biotech Showcase Digital 2021?

James Sapirstein, President & CEO, and the senior management team of AzurRx will represent the company at the conference.

What are the key focus areas for AzurRx during the conference?

The key focus areas include discussing the company's business, clinical development programs, and anticipated milestones for 2021.

What therapeutic candidate is AzurRx primarily focusing on?

AzurRx is primarily focusing on its lead therapeutic candidate, MS1819, for treating exocrine pancreatic insufficiency.

What is the significance of the Biotech Showcase Digital 2021 for AzurRx?

The Biotech Showcase Digital 2021 conference is significant for AzurRx as it provides an opportunity to connect with investors and showcase its clinical development plans.